LGND Ligand Pharmaceuticals Inc

Price (delayed)

$144.40

Market cap

$2.4B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.18

Enterprise value

$2.81B

Sector: Healthcare
Industry: Biotechnology

Highlights

The revenue has surged by 55% year-on-year and by 30% since the previous quarter
The gross profit has grown by 43% year-on-year and by 27% since the previous quarter
Ligand Pharmaceuticals's net income has plunged by 100% YoY but it has soared by 81% from the previous quarter
Ligand Pharmaceuticals's EPS has shrunk by 101% YoY
Ligand Pharmaceuticals's quick ratio has shrunk by 93% YoY and by 76% QoQ

Key stats

What are the main financial stats of LGND
Market
Shares outstanding
16.61M
Market cap
$2.4B
Enterprise value
$2.81B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.27
Price to sales (P/S)
12.54
EV/EBIT
166.31
EV/EBITDA
62.6
EV/Sales
15.06
Earnings
Revenue
$186.42M
EBIT
$16.88M
EBITDA
$44.85M
Free cash flow
$51.49M
Per share
EPS
-$0.18
Free cash flow per share
$3.18
Book value per share
$44.09
Revenue per share
$11.52
TBVPS
$34.99
Balance sheet
Total assets
$1.36B
Total liabilities
$652.76M
Debt
$456.41M
Equity
$709.53M
Working capital
$400.45M
Liquidity
Debt to equity
0.64
Current ratio
5
Quick ratio
4.68
Net debt/EBITDA
9.12
Margins
EBITDA margin
24.1%
Gross margin
83.7%
Net margin
-1.6%
Operating margin
13.9%
Efficiency
Return on assets
-0.2%
Return on equity
-0.4%
Return on invested capital
1.6%
Return on capital employed
1.3%
Return on sales
9.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LGND stock price

How has the Ligand Pharmaceuticals stock price performed over time
Intraday
1.9%
1 week
-2.58%
1 month
-28.88%
1 year
35.42%
YTD
45.2%
QTD
45.2%

Financial performance

How have Ligand Pharmaceuticals's revenue and profit performed over time
Revenue
$186.42M
Gross profit
$156M
Operating income
$25.85M
Net income
-$2.99M
Gross margin
83.7%
Net margin
-1.6%
Ligand Pharmaceuticals's net income has plunged by 100% YoY but it has soared by 81% from the previous quarter
The net margin has plunged by 100% YoY but it has soared by 86% from the previous quarter
Ligand Pharmaceuticals's operating margin has shrunk by 98% YoY
The company's operating income has shrunk by 97% YoY

Growth

What is Ligand Pharmaceuticals's growth rate over time

Valuation

What is Ligand Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.27
P/S
12.54
EV/EBIT
166.31
EV/EBITDA
62.6
EV/Sales
15.06
Ligand Pharmaceuticals's EPS has shrunk by 101% YoY
LGND's P/B is 49% higher than its last 4 quarters average of 2.2 but 33% lower than its 5-year quarterly average of 4.9
The equity has declined by 8% year-on-year
The revenue has surged by 55% year-on-year and by 30% since the previous quarter
The price to sales (P/S) is 29% lower than the 5-year quarterly average of 17.7 but 13% higher than the last 4 quarters average of 11.1

Efficiency

How efficient is Ligand Pharmaceuticals business performance
Ligand Pharmaceuticals's ROIC has soared by 167% from the previous quarter but it has plunged by 97% YoY
The company's return on equity has shrunk by 101% YoY but it has surged by 83% QoQ
The ROA has shrunk by 101% YoY but it has soared by 83% QoQ
Ligand Pharmaceuticals's return on sales has shrunk by 99% YoY but it has surged by 69% QoQ

Dividends

What is LGND's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LGND.

Financial health

How did Ligand Pharmaceuticals financials performed over time
The company's total assets is 109% higher than its total liabilities
Ligand Pharmaceuticals's quick ratio has shrunk by 93% YoY and by 76% QoQ
LGND's current ratio has dropped by 92% year-on-year and by 75% since the previous quarter
The debt is 36% less than the equity
The debt to equity has contracted by 25% YoY and by 3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.